%0 Journal Article %1 Turan2024 %A Turan, Onur %A Ogan, Nalan %A Bozkus, Fulsen %A Sarıoğlu, Nurhan %A Turan, Pakize Ayşe %A Satıcı, Celal %D 2024 %I Springer Science and Business Media LLC %K COPD LABA LAMA %N 6 %P 847--853 %R 10.1007/s00228-024-03637-1 %T Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients? %V 80

@article{Turan2024, added-at = {2024-05-21T10:59:48.000+0200}, author = {Turan, Onur and Ogan, Nalan and Bozkus, Fulsen and Sarıoğlu, Nurhan and Turan, Pakize Ayşe and Satıcı, Celal}, biburl = {https://www.bibsonomy.org/bibtex/2959e13318a81e7eac5f0267cf11c172a/jepcastel}, doi = {10.1007/s00228-024-03637-1}, interhash = {92652d6d2efea2ce5be09359590d489f}, intrahash = {959e13318a81e7eac5f0267cf11c172a}, issn = {1432-1041}, journaltitle = {European Journal of Clinical Pharmacology}, keywords = {COPD LABA LAMA}, number = 6, pages = {847--853}, publisher = {Springer Science and Business Media LLC}, timestamp = {2024-05-21T10:59:48.000+0200}, title = {Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?}, volume = 80, year = 2024 }